Page last updated: 2024-11-05

n-phenylmaleimide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-phenylmaleimide is a cyclic imide that is used as a reagent in organic synthesis. It is a white solid that is soluble in most organic solvents. It is typically synthesized via the reaction of maleic anhydride with aniline. N-phenylmaleimide is a versatile reagent that can be used to prepare a variety of different compounds, including polymers, pharmaceuticals, and agrochemicals. It is an important building block in the synthesis of various nitrogen-containing heterocycles. Its unique structure and reactivity make it a valuable tool for organic chemists. Its applications include polymer synthesis, where it is used as a monomer for the production of polyimides, a class of high-performance polymers with excellent thermal stability and mechanical strength. It is also used as a building block for pharmaceuticals and agrochemicals, where its ability to form stable adducts with various functional groups allows for the design of molecules with specific biological activities. N-phenylmaleimide is also an important reagent in the synthesis of heterocyclic compounds. For instance, it can be used to prepare the important heterocyclic compounds, such as phthalimides and succinimides. N-phenylmaleimide has been extensively studied for its reactivity in Diels-Alder reactions and its use in the synthesis of various functionalized compounds. The interest in this compound stems from its ability to act as a dienophile in Diels-Alder reactions, which allows for the efficient construction of complex cyclic systems. Furthermore, N-phenylmaleimide has shown promise in the development of new materials with advanced properties, such as high thermal stability, excellent mechanical strength, and unique optical properties. These applications, along with the potential to develop new synthetic methods, have sparked significant research interest in this compound.'

N-phenylmaleimide: structure in Merck Index, 9th ed, #7104 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13662
CHEMBL ID76012
SCHEMBL ID18713
MeSH IDM0091723

Synonyms (70)

Synonym
HMS1473M19
AC-20477
CHEMBL76012 ,
5-21-10-00009 (beilstein handbook reference)
n-fenylimid kyseliny maleinove
ec 213-382-0
unii-9u9kt462vw
9u9kt462vw ,
UPCMLD0ENAT5455323:001
nsc8183
maleinanil
n-phenylmaleimide
nsc-8183
maleanil
maleimidobenzene
wln: t5vnvj br
941-69-5
maleimide, n-phenyl-
1h-pyrrole-2, 1-phenyl-
1h-pyrrole-2,5-dione, 1-phenyl-
einecs 213-382-0
n-fenylimid kyseliny maleinove [czech]
nsc 8183
ai3-01186
brn 0125098
IDI1_019601
CHEMDIV3_000283
EU-0033370
n-phenylmaleimide, 97%
NCGC00176508-01
AKOS000249503
BRD-K27141229-001-01-9
1-phenylpyrrole-2,5-dione
inchi=1/c10h7no2/c12-9-6-7-10(13)11(9)8-4-2-1-3-5-8/h1-7h
hidbrosjwzygsz-uhfffaoysa-
P0900
bdbm50300353
1-phenyl-pyrrole-2,5-dione
1-phenyl-1h-pyrrole-2,5-dione
NCGC00176508-02
dtxcid8021274
NCGC00254580-01
cas-941-69-5
tox21_300672
dtxsid0041274 ,
1-phenyl-2,5-dihydro-1h-pyrrole-2,5-dione
FT-0633165
AM20041441
n-phenylmaleimide [mi]
SCHEMBL18713
n-phenyl maleimide
n-phenyl maleic imide
n-phenyl-maleinimide
n-phenylpyrrole-2,5-dione
1-phenyl-1h-pyrrole-2,5-dione #
pyrrole-1,5-dione, n-phenyl-
W-100209
STR03760
mfcd00005502
F0266-1301
n-phenylmaleimide, >=98.0% (hplc)
D77858
CS-W019590
Z104481692
STL195609
n-phenylmale-imide
n-phenylmaleinimde
Q27273236
EN300-20769
PD135235

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" While the dose-response curves for [3H]dexamethasone binding versus thiol reagent are normally sigmoidal, an unusual bimodal curve is obtained with MMTS in which dexamethasone binding is eliminated at low, but maintained at intermediate, MMTS concentrations."( Steroid binding to hepatoma tissue culture cell glucocorticoid receptors involves at least two sulfhydryl groups.
Miller, NR; Simons, SS, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (41)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency22.44580.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency35.57420.002541.796015,848.9004AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency25.24273.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency7.27740.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency61.64480.173734.304761.8120AID1346924
SMAD family member 3Homo sapiens (human)Potency61.64480.173734.304761.8120AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency5.67810.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency28.84840.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036; AID743042; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency68.58960.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency27.30600.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency46.67140.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency64.86010.000417.946075.1148AID1346784; AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency56.40200.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency8.47920.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency53.97480.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency56.02620.375827.485161.6524AID743217; AID743220; AID743239
pregnane X nuclear receptorHomo sapiens (human)Potency68.58960.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency61.51370.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency34.89540.001024.504861.6448AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency35.17620.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency13.49100.023723.228263.5986AID743222; AID743223; AID743241
caspase-3Homo sapiens (human)Potency68.58960.013326.981070.7614AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency10.87070.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency27.43850.001628.015177.1139AID1224843; AID1224895; AID1259385; AID1259395
activating transcription factor 6Homo sapiens (human)Potency61.64480.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency47.754419.739145.978464.9432AID1159509; AID1159518
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency36.75370.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency14.22640.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency5.15200.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency30.84110.037617.082361.1927AID1259364; AID1259388
heat shock protein beta-1Homo sapiens (human)Potency29.56290.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency16.50830.000627.21521,122.0200AID743202; AID743219
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency61.13060.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency61.53610.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency61.13060.001551.739315,848.9004AID1259244
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency68.58960.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency68.58960.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)229.00000.00020.59827.0000AID439745
TrypsinSus scrofa (pig)Ki800.00000.09000.09000.0900AID215581
Histone acetyltransferase RTT109Saccharomyces cerevisiae S288CIC50 (µMol)8.20000.13004.63178.8000AID1199844; AID1199845
Monoglyceride lipaseHomo sapiens (human)IC50 (µMol)15.90000.00091.126810.0000AID439744
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (154)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
lipid metabolic processMonoglyceride lipaseHomo sapiens (human)
fatty acid biosynthetic processMonoglyceride lipaseHomo sapiens (human)
inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of signal transductionMonoglyceride lipaseHomo sapiens (human)
arachidonic acid metabolic processMonoglyceride lipaseHomo sapiens (human)
triglyceride catabolic processMonoglyceride lipaseHomo sapiens (human)
acylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of inflammatory responseMonoglyceride lipaseHomo sapiens (human)
regulation of sensory perception of painMonoglyceride lipaseHomo sapiens (human)
monoacylglycerol catabolic processMonoglyceride lipaseHomo sapiens (human)
regulation of endocannabinoid signaling pathwayMonoglyceride lipaseHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (46)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
lysophospholipase activityMonoglyceride lipaseHomo sapiens (human)
protein bindingMonoglyceride lipaseHomo sapiens (human)
protein homodimerization activityMonoglyceride lipaseHomo sapiens (human)
acylglycerol lipase activityMonoglyceride lipaseHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
endoplasmic reticulum membraneMonoglyceride lipaseHomo sapiens (human)
cytosolMonoglyceride lipaseHomo sapiens (human)
plasma membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
membraneMonoglyceride lipaseHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID322163Antifungal activity against Candida krusei C 117-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID322164Antifungal activity against Candida kefyr C 123-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID596446Antifungal activity against Cryptococcus neoformans ATCC 322642011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID215581Inhibition constant (Ki) against trypsin enzyme for the conversion of water-soluble compound to fluorescent oil-soluble compound1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
A rapid method to identify exo-protease inhibitors.
AID322154Antifungal activity against Candida albicans C 126-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID1199844Inhibition of Vps75-stimulated recombinant Saccharomyces cerevisiae histone acetyltransferase Rtt109 using Asf1-dH3-H4 as substrate assessed as coenzyme A production after 45 mins by CPM based HTS assay2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.
AID596525Antifungal activity against Aspergillus flavus ATCC 91702011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID439744Displacement of [3H]2-OG from human MGL by liquid scintillation counting2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors.
AID322159Antifungal activity against Candida glabrata C 115-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID466512Toxicity in mouse assessed as mortality at 100 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID322158Antifungal activity against Candida albicans C 130-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID596447Antifungal activity against Aspergillus fumigatus ATCC 269342011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID596439Cytotoxicity against human MCF7 cells assessed as cell growth after 2 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID466511Toxicity in mouse assessed as mortality at 30 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID596441Cytotoxicity against human SF268 cells assessed as cell growth after 2 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID322162Antifungal activity against Candida coliculosa C 122-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID596526Antifungal activity against Aspergillus niger ATCC 90292011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID1203998Antiinflammatory activity against mouse MB49-I cells assessed as inhibition of IFN-gamma/TNFalpha-NO production pretreated at 10 uM after 24 hrs by Griess reaction relative to vehicle treated control2015European journal of medicinal chemistry, , Volume: 96Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells.
AID1199846Inhibition of Vps75-stimulated recombinant Saccharomyces cerevisiae histone acetyltransferase Rtt109 assessed as H3K56 acetylated product at 125 uM after 45 mins by Slot bolt inhibiton assay2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.
AID322174Antifungal activity against Candida albicans ATCC 10231 preincubated for 7 days analysed after 24 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID596440Cytotoxicity against human H460 cells assessed as cell growth after 2 days by sulforhodamine B assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID596444Antifungal activity against Candida tropicalis C 131 20002011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID322155Antifungal activity against Candida albicans C 127-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID466506Cytotoxicity against human CEM cells2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID466507Cytotoxicity against mouse L1210 cells2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID1199862Fluorescence quenching in HTS buffer with 20 uM 7-diethylamino-3-(4'-maleimidyl-phenyl)-4-methylcoumarin assessed as fluorescence signal reduction at 10 uM after 10 mins2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.
AID322161Antifungal activity against Candida lusitaniae C 131-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID322160Antifungal activity against Candida parapsilosis C 124-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID596527Antifungal activity against Microsporum gypseum C 115 20002011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID322171Antifungal activity against Candida albicans ATCC 10231 pre-incubated for 4 days analysed after 24 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID322152Antifungal activity against Candida albicans ATCC 10231 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID322165Antifungal activity against Candida tropicalis C 137-1997 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID322153Antifungal activity against Candida albicans C 125-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID322157Antifungal activity against Candida albicans C 129-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID439748Displacement of [3H]2-OG from human MGL at 16 uM treated for 15 mins before addition of 2-OG by liquid scintillation counting2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors.
AID596529Antifungal activity against Trichophyton mentagrophytes ATCC 99722011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID322169Antifungal activity against Candida albicans ATCC 10231 pre-incubated for 2 days analysed after 24 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID1199848Fluorescence quenching assessed as fluorescence signal reduction at 10 uM after 10 mins2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.
AID596443Antifungal activity against Candida albicans ATCC 102132011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID1199850Fluorescence quenching in HTS buffer with 7.5 uM CoA assessed as fluorescence signal reduction at 10 uM after 10 mins2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.
AID322173Antifungal activity against Candida albicans ATCC 10231 pre-incubated for 6 days analysed after 24 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID322156Antifungal activity against Candida albicans C 128-2000 after 48 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID466505Cytotoxicity against human Molt4/C8 cells2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID596445Antifungal activity against Saccharomyces cerevisiae ATCC 97632011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID1667757Inhibition of SET7 (unknown origin) using biotinylated histone polypeptide as substrate at 100 uM in presence of SAM by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors.
AID1199849Fluorescence quenching in HTS buffer assessed as fluorescence signal reduction at 10 uM after 10 mins2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.
AID596528Antifungal activity against Trichophyton rubrum C 113 20002011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID439749Displacement of [3H]2-OG from human MGL at 16 uM treated for 30 mins before addition of 2-OG by liquid scintillation counting2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors.
AID322170Antifungal activity against Candida albicans ATCC 10231 pre-incubated for 3 days analysed after 24 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID322166Antifungal activity against Candida albicans ATCC 10231 within 90 mins by time-to-kill study2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID596442Cytotoxicity against human erythrocytes assessed as hemolysis by spectrometric analysis2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.
AID1199847Inhibition of Vps75-stimulated recombinant Saccharomyces cerevisiae histone acetyltransferase Rtt109 assessed as H3K27 acetylated product at 125 uM after 45 mins by Slot bolt inhibiton assay2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.
AID1199845Inhibition of Vps75-stimulated recombinant Saccharomyces cerevisiae histone acetyltransferase Rtt109 using Asf1-dH3-H4 as substrate assessed as coenzyme A production after 45 mins by CoA-based HTS counter screen assay2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.
AID322168Antifungal activity against Candida albicans ATCC 10231 pre-incubated for 1 day analysed after 24 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID322167Antifungal activity against Candida albicans ATCC 10231 after 24 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID1203999Antiinflammatory activity against mouse MB49-I cells assessed as inhibition of IFN-gamma/TNFalpha-NO production pretreated at 50 uM after 24 hrs by Griess reaction relative to vehicle treated control2015European journal of medicinal chemistry, , Volume: 96Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells.
AID322172Antifungal activity against Candida albicans ATCC 10231 pre-incubated for 5 days analysed after 24 hrs by CLSI M27-A2 method2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
N-Phenyl and N-phenylalkyl-maleimides acting against Candida spp.: time-to-kill, stability, interaction with maleamic acids.
AID439745Displacement of [3H]ethanolamine from human recombinant FAAH by liquid scintillation counting2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors.
AID466513Toxicity in mouse assessed as mortality at 300 mg/kg, ip after 4 hrs2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Derivatives of aryl amines containing the cytotoxic 1,4-dioxo-2-butenyl pharmacophore.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (11.94)18.7374
1990's18 (26.87)18.2507
2000's16 (23.88)29.6817
2010's21 (31.34)24.3611
2020's4 (5.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.85 (24.57)
Research Supply Index4.23 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index56.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other68 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]